Viagra and Cancer: What New Sildenafil Research Really Shows

Can Viagra Help Fight Cancer? What New Research on Sildenafil Really Shows

A new 2026 study has put sildenafil, the active ingredient in Viagra, into the spotlight of cancer research. Scientists found that sildenafil can interfere with cholesterol trafficking inside cancer cells and, in laboratory and animal models, reduce processes linked to cancer spread and metastasis. The researchers also found an association between sildenafil use and survival in a retrospective analysis of health records.

However, this does not mean that Viagra is a cancer treatment or that people with cancer should start taking sildenafil. The most important findings from the new study come from laboratory and animal research, while the human data were observational. Clinical trials are still needed to determine whether sildenafil can safely and effectively be used as part of cancer treatment.

This article explains what the latest research actually found, how sildenafil may affect cancer cells, what earlier studies have shown about chemotherapy and heart protection, and what remains unknown.

What Is Sildenafil and How Does Viagra Work?

Sildenafil is the active ingredient in Viagra and belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.

Sildenafil works by blocking the PDE5 enzyme. This allows a signalling molecule called cyclic guanosine monophosphate (cGMP) to remain active for longer. Increased cGMP helps relax smooth muscle and improve blood flow.

This mechanism is responsible for sildenafil’s established medical effects, particularly in erectile dysfunction. Sildenafil is also used in specific formulations for pulmonary arterial hypertension.

The possible connection between sildenafil and cancer is different. Researchers are investigating whether changes in the PDE5-cGMP pathway can affect processes inside cancer cells, including cell survival, metabolism, movement and the ability to spread.

These possible anti-cancer effects remain an area of research. They should not be confused with sildenafil’s established clinical uses.

What Did the New 2026 Sildenafil and Cancer Study Find?

The most important recent study was published online on July 14, 2026, in the journal Cancer Research. It was conducted by researchers from the Weizmann Institute of Science, the U.S. National Cancer Institute, Clalit Health Services and collaborating institutions.

The study was titled:

“PDE5a Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking Through a Non-canonical cGMP-Dependent Pathway.”

The paper investigated how PDE5a inhibitors, including sildenafil, affect cancer biology.

The researchers used several types of experimental models, including human and mouse cancer models, patient-derived tumor organoids and a retrospective analysis of digital health records.

The major findings included:

• Sildenafil increased cholesterol accumulation inside lysosomes, which are structures involved in cellular recycling.
• Increased cGMP affected NPC1, a protein involved in moving cholesterol out of lysosomes.
• Disrupted cholesterol trafficking reduced the availability of cholesterol needed for several cellular processes.
• Cancer cells showed reduced migration and invasion in experimental models.
• Sildenafil restricted metastatic behavior in mouse models.
• Combining sildenafil with statins produced additive anti-metastatic effects in the experimental models.
• A retrospective analysis of health records found an association between sildenafil use and improved survival.

These findings are scientifically interesting because they suggest that a drug already used for another medical purpose may influence cancer biology through a previously underappreciated metabolic pathway.

But there is an important qualification: the study did not prove that taking Viagra treats cancer or prevents cancer from spreading in humans.

How Could Sildenafil Potentially Affect Cancer Spread?

The most interesting part of the 2026 research involves cholesterol trafficking.

Cholesterol is often discussed in relation to heart health, but cells also need cholesterol for normal structure and function. Cancer cells can have particularly high metabolic demands because they grow, divide and migrate rapidly.

The researchers found evidence that sildenafil can interfere with how cancer cells move cholesterol inside the cell.

The proposed pathway can be simplified into five steps.

1. Sildenafil inhibits PDE5a

Sildenafil inhibits PDE5a, which increases levels of the signalling molecule cGMP.

2. Increased cGMP affects NPC1

The study found that elevated cGMP can interact with NPC1, a lysosomal cholesterol transporter.

NPC1 normally helps move cholesterol out of lysosomes.

3. Cholesterol becomes trapped

When this process is disrupted, cholesterol accumulates inside lysosomes instead of being distributed normally throughout the cell.

4. Cancer-cell functions are disrupted

The resulting reduction in cholesterol availability can affect cellular structures such as membrane lipid rafts and mitochondrial energy production.

5. Cancer cells become less capable of spreading

In the experimental models, these changes were associated with reduced cancer-cell migration, invasion and metastatic capacity.

This mechanism is one of the main reasons the study has attracted attention.

However, it is important to remember that demonstrating a mechanism in cancer cells and mice is not the same as demonstrating a treatment effect in cancer patients.

What Did the Human Data Show?

The 2026 study also included an analysis of digital health records.

Researchers found that people who had used sildenafil had better survival outcomes in the dataset. They also reported an additional benefit associated with combining sildenafil and statins.

At first glance, this may sound like evidence that Viagra improves cancer survival. It is not that simple.

The human component was retrospective and observational. Researchers examined existing healthcare information rather than randomly assigning cancer patients to receive sildenafil or placebo.

That means the study can identify an association, but it cannot establish that sildenafil caused the difference in survival.

For example, people who use sildenafil may differ from non-users in other ways that influence health outcomes. Researchers must account for these possible confounding factors, and observational research cannot completely replace randomized clinical trials.

There is also an important distinction between medication use before diagnosis and deliberately giving sildenafil to patients after they develop cancer.

The 2026 study does not establish that cancer patients who start taking Viagra after diagnosis will experience slower tumor growth or longer survival.

That question requires prospective clinical trials.

Can Viagra Make Chemotherapy More Effective?

Another area of sildenafil research involves chemotherapy.

Several laboratory and animal studies have investigated whether sildenafil can make certain cancer cells more sensitive to chemotherapy drugs.

One important example is doxorubicin, an established chemotherapy drug.

A 2010 study published in PNAS found that sildenafil enhanced doxorubicin-induced cancer-cell death in prostate cancer cell models. In mice carrying prostate cancer xenografts, the combination also produced greater tumor-growth inhibition than doxorubicin alone.

The researchers also reported improved cardiac function in the mice receiving the combination.

Other preclinical research has investigated sildenafil with different anticancer agents and cancer models.

These findings are useful because they suggest that PDE5 inhibition could potentially influence how some cancer cells respond to treatment.

But there is a major limitation:

Most of this evidence comes from laboratory or animal studies.

A result seen in cancer cells in a laboratory does not automatically translate into the same result in a person receiving chemotherapy.

Therefore, it would be inaccurate to say that Viagra is proven to make chemotherapy more effective.

A more accurate statement is:

Preclinical research suggests that sildenafil may enhance the effects of certain chemotherapy drugs in specific experimental cancer models, but this has not established sildenafil as a standard chemotherapy treatment in humans.

Can Sildenafil Protect the Heart During Chemotherapy?

This question is particularly interesting because some chemotherapy drugs, especially anthracyclines such as doxorubicin, can damage the heart.

Earlier animal research produced promising results. A 2010 PNAS study reported that sildenafil reduced doxorubicin-related cardiac dysfunction in mice while also enhancing the drug’s anti-tumor effects.

However, promising animal findings were not confirmed in subsequent human research.

What did the human clinical trials show?

A randomized double-blind clinical trial called SILDAT-TAHA6 studied whether sildenafil could prevent anthracycline-related cardiac toxicity.

The trial enrolled 60 patients, with 52 included in the final analysis. Patients received either sildenafil or placebo alongside their chemotherapy.

The researchers found no significant difference between the groups in the decline of left ventricular ejection fraction. Cancer-therapy-related cardiac dysfunction occurred in 41.6% of the sildenafil group compared with 42.8% of the control group.

The researchers concluded that sildenafil did not provide a meaningful benefit for preventing anthracycline-induced cardiac toxicity.

Another small randomized study involving 27 patients also examined sildenafil alongside doxorubicin-based chemotherapy. It found that adding sildenafil was feasible and did not demonstrate a clear cardioprotective effect.

This difference between animal and human findings is important.

Animal research showed potential heart protection, but randomized human evidence has not confirmed that benefit.

Therefore, sildenafil should not be taken specifically to protect the heart during chemotherapy unless it is being used under appropriate medical supervision or within a clinical research setting.

Does Viagra Treat or Cure Cancer?

No. Viagra is not an approved cancer treatment or cure.

The recent research does not change the established role of sildenafil.

Researchers are interested in sildenafil because it affects PDE5 and cGMP signalling and may influence cancer-related biological processes. The 2026 study adds a particularly interesting mechanism involving cholesterol trafficking and cancer metastasis.

But there is still a large difference between:

“A drug shows promising anti-cancer effects in research”

and

“The drug is an effective cancer treatment for patients.”

Before sildenafil could be considered an established cancer therapy, researchers would need strong evidence from well-designed human clinical trials.

Those trials would need to determine whether sildenafil:

• Actually improves cancer outcomes
• Works for particular cancer types
• Reduces metastasis in humans
• Works safely with standard cancer treatments
• Has an effective and safe dose
• Produces meaningful benefits that outweigh its risks

Until then, sildenafil remains a research interest rather than an approved cancer treatment.

Can Cancer Patients Take Viagra?

Cancer patients may experience erectile dysfunction for many reasons, including the effects of cancer itself, surgery, hormonal changes, nerve damage or certain treatments.

Sildenafil may sometimes be prescribed for erectile dysfunction in appropriate patients, but having cancer can make medication decisions more complicated.

Cancer patients may be taking several medicines at the same time, and their cardiovascular health may also need special consideration.

One particularly important interaction involves nitrates.

Sildenafil should not be combined with nitrate medicines because the combination can cause a dangerous drop in blood pressure.

Other medicines can also affect sildenafil’s safety or how it is metabolized.

For this reason, someone receiving cancer treatment should tell their oncologist or other qualified healthcare professional about all medicines they are taking before using sildenafil.

Most importantly, cancer patients should not start taking Viagra because they have read about the 2026 cancer research.

The research does not provide enough evidence to recommend sildenafil as a way to slow cancer or prevent metastasis.

Viagra and Cancer: What the Research Suggests vs What It Does Not Prove

The easiest way to understand the current evidence is to separate the findings by evidence level.

Research suggests

• Sildenafil can affect the PDE5-cGMP signalling pathway.
• Experimental studies show that sildenafil can disrupt cholesterol trafficking in cancer cells.
• The 2026 study found reduced migration and metastatic behavior in several experimental cancer models.
• Sildenafil enhanced the effects of doxorubicin in certain preclinical prostate cancer models.
• Retrospective health-record data found an association between sildenafil use and survival outcomes.
• Researchers are investigating whether PDE5 inhibition could eventually have a role in cancer treatment.

Research does not prove

• Viagra cures cancer.
• Sildenafil prevents cancer in healthy people.
• Sildenafil stops cancer from spreading in humans.
• Viagra replaces chemotherapy, surgery, radiation or immunotherapy.
• Sildenafil makes chemotherapy more effective in all cancer patients.
• Sildenafil protects the heart from chemotherapy-related damage in humans.
• People with cancer should start taking Viagra for anti-cancer purposes.

The difference between these two lists is essential when interpreting headlines about this research.

What Researchers Need to Study Next

The 2026 findings provide a reason for further investigation, but several important questions remain unanswered.

Larger human clinical trials

Researchers need randomized controlled trials to determine whether sildenafil actually improves outcomes in cancer patients.

Specific cancer types

Different cancers have different biological characteristics. Future research will need to determine which cancers, if any, are most likely to respond to PDE5 inhibition.

Appropriate dose

A laboratory concentration that affects cancer cells cannot simply be translated into a safe human dose.

Researchers must determine whether the biological effect can be achieved using doses that are safe and tolerable in people.

Combination treatments

The new study found additive anti-metastatic effects when sildenafil was combined with statins in experimental models.

Future clinical research would need to determine whether this combination has meaningful benefits in humans and whether it is safe.

Long-term safety

Cancer treatment can already place significant demands on the cardiovascular system and other organs. Researchers would need to carefully evaluate the long-term safety of sildenafil in different cancer populations.

Confirmation of the mechanism in humans

Finally, researchers need to determine whether the cholesterol-trafficking mechanism identified in laboratory and animal models also occurs in human tumors at clinically achievable sildenafil concentrations.

Until these questions are answered, the findings should be viewed as promising research rather than established cancer treatment.

The Bottom Line: Can Viagra Help Fight Cancer?

The latest research gives scientists an interesting reason to investigate sildenafil in cancer treatment, but it is too early to say that Viagra can fight cancer in patients.

The strongest evidence from the 2026 study shows that sildenafil affected cholesterol trafficking and reduced metastatic behavior in laboratory and animal models. The same study also found an association between sildenafil use and survival in retrospective health records.

However, observational human data cannot prove that sildenafil caused better outcomes, and laboratory or animal findings do not automatically translate into successful human treatments.

Earlier research has also suggested that sildenafil may enhance certain chemotherapy effects in experimental models, while randomized human studies have not confirmed a protective effect against anthracycline-related heart damage.

So the most accurate conclusion is:

Sildenafil is a promising subject of cancer research, but Viagra is not currently a cancer treatment, and people should not take it to prevent or treat cancer based on these findings.

For patients who already use or are considering sildenafil for erectile dysfunction, the appropriate decision should be based on their medical history, other medicines and advice from a qualified healthcare professional.

FAQ Section

Can Viagra cure cancer?

No. Viagra (sildenafil) is not a cure for cancer. It is approved only for erectile dysfunction and pulmonary arterial hypertension. Laboratory and animal studies suggest potential biological effects on cancer cells, but these findings have not been proven in human clinical trials.aacrjournals+1

Can sildenafil stop cancer from spreading?

Preclinical studies in cells and mice suggest sildenafil may reduce cancer cell migration and metastasis by disrupting cholesterol trafficking. However, this has not been proven in human patients. Observational data show associations, not causation.aacrjournals+2

Does Viagra make chemotherapy more effective?

Laboratory and animal studies indicate sildenafil may enhance certain chemotherapy drugs’ effectiveness (e.g., doxorubicin, cisplatin) in specific cancer types. However, no large human trials have established this as standard practice.pubmed.ncbi.nlm.nih+2

Can cancer patients take sildenafil?

Cancer patients should consult their oncologist before taking sildenafil. It may interact with certain medications (especially nitrates) and may not be appropriate for all patients, particularly those with cardiovascular issues or receiving specific cancer treatments.pmc.ncbi.nlm.nih+1

Is sildenafil being studied as a cancer treatment?

Yes. Researchers are investigating sildenafil’s potential as an adjunct cancer therapy in preclinical models and early-phase clinical trials. However, it is not an approved cancer treatment, and results are not yet definitive.nature+2

What does the latest Viagra cancer study show?

The July 2026 Cancer Research study found that sildenafil disrupted cholesterol trafficking in cancer cells, reducing metastasis in mouse models. Retrospective clinical data suggested improved survival among sildenafil users, especially with statins. Human trials are still needed.aacrjournals+2

Does sildenafil kill cancer cells?

In laboratory studies, sildenafil induced apoptosis (programmed cell death) in certain cancer cell lines and enhanced chemotherapy-induced cell death. This has not been established as a treatment effect in human patients.pubmed.ncbi.nlm.nih+2

Is Viagra approved for cancer treatment?

No. Viagra (sildenafil) is not approved by any regulatory agency for cancer treatment. It is approved only for erectile dysfunction and pulmonary arterial hypertension.nature+1

Can sildenafil protect the heart during chemotherapy?

Human clinical trials (SILDAT-TAHA6 2022; VCU pilot 2018) found sildenafil did not protect the heart during anthracycline chemotherapy, despite promising animal studies. It should not be used for this purpose outside clinical trials.pmc.ncbi.nlm.nih+1

What is the connection between Viagra and cancer?

The connection is scientific research interest, not clinical use. Sildenafil’s effect on cGMP signalling may influence cancer cell metabolism, migration, and response to chemotherapy in laboratory settings. This has generated research hypotheses, not treatment recommendations.nature+2

References and Scientific Sources

1. 1. Ariav Y, Hayek S, Cantore T, et al. “PDE5a Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking Through a Non-canonical cGMP-Dependent Pathway.” Cancer Research. 2026. DOI: 10.1158/0008-5472.CAN-26-1818.
      Supports the 2026 findings concerning sildenafil, cGMP, NPC1, cholesterol trafficking, cancer-cell migration, metastasis, statin combination and retrospective health-record analysis.
   2. Attar A, Heydari M, Abtahi F, et al. “Sildenafil for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: A Phase I/II Randomized Clinical Trial, SILDAT-TAHA6 Trial.” Cardiology Research and Practice. 2022;2022:5681510.
      Supports the human evidence showing no significant cardioprotective benefit from sildenafil during anthracycline treatment.
   3. Das A, Durrant D, Mitchell C, et al. “Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction.” Proceedings of the National Academy of Sciences. 2010;107(42):18202–18207.
      Supports the preclinical findings involving sildenafil, doxorubicin, prostate cancer models and cardiac effects in mice.
   4. Poklepovic A, Qu Y, et al. “Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers.” Cardio-Oncology. 2018.
      Provides additional human evidence regarding sildenafil used alongside doxorubicin-based chemotherapy and its lack of demonstrated cardioprotective benefit.